Overview

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

Status:
Completed

Trial end date:
2022-10-30

Target enrollment:

Participant gender:

Summary

A Phase II study on dose optimization of fruquintinib in elderly metastatic colorectal cancer patients refractory to standard treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Zhen-Yu Ding